Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624
This examiner grants 83% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18256629 | Process for the preparation of 4-(3,5-difluorophenyl)-N-[3-(6-methylpyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-6,7-dihydro-5H-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine | Non-Final OA | Hoffmann-La Roche Inc. |
| 18076383 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | Final Rejection | Hoffmann-La Roche Inc. |
| 18072223 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | Non-Final OA | Northwestern University |
| 18315472 | N-[2-({4-[3-(ANILINO)-4-OXO-4,5,6,7-TETRAHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-2-YL]PYRIDIN-3-YL)OXY)ETHYL]PROP-2-ENAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 18313652 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | Non-Final OA | Merck Patent GmbH |
| 17997091 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | Non-Final OA | Pfizer Inc. |
| 17971318 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | Non-Final OA | Atea Pharmaceuticals, Inc. |
| 18267235 | IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS | Non-Final OA | UCB Biopharma SRL |
| 18458292 | THERAPEUTIC AGENT FOR CANCER OF PATIENT WITH DECREASE IN RB1 FUNCTION USING MYT1 INHIBITOR AND CHEMOTHERAPEUTIC AGENT IN COMBINATION, AND TREATMENT METHOD THEREOF | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18440293 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | Non-Final OA | Biomea Fusion, Inc. |
| 18168874 | JAK INHIBITOR COMPOUND AND USE THEREOF | Non-Final OA | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. |
| 17786504 | THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | Final Rejection | TAIHO PHARMACEUTICAL CO., LTD. |
| 18134495 | BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF | Final Rejection | SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. |
| 18001148 | ARYLACETAMIDE ANALOGS OF PIPERAZINE-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES | Non-Final OA | Saint Louis University |
| 18269670 | FIVE-MEMBERED RING DERIVATIVE AND MEDICAL USE THEREOF | Non-Final OA | Xizang Haisco Pharmaceutical Co., Ltd. |
| 18497879 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | Non-Final OA | Escient Pharmaceuticals, Inc. |
| 18487254 | Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide | Final Rejection | Acerta Pharma B.V. |
| 18066275 | PYRAZINE COMPOUNDS AND USES THEREOF | Non-Final OA | Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
| 18279377 | 7-Morpholino-L,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | Non-Final OA | Provincial Health Services Authority |
| 18270781 | PROCESS FOR PREPARING HIGH PURITY DEGREE LAROTRECTINIB | Non-Final OA | OLON S.P.A. |
| 18261896 | PROCESS FOR MAKING IBRUTINIB | Non-Final OA | Synthon B.V. |
| 18220475 | METHOD FOR PREVENTING AND/OR TREATING LIVER FIBROSIS BY USING 6-METHOXYBENZOXAZOLINONE AND COIX LACHRYMA-JOBI L. EXTRACT COMPRISING 6-METHOXYBENZOXAZOLINONE | Non-Final OA | Taichung District Agricultural Research and Extension Station, Ministry of Agriculture |
| 18024236 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | Non-Final OA | Centessa Pharmaceuticals (UK) Limited |
| 18344167 | Pyrazolopyrimidine compounds as kinase Inhibitors | Final Rejection | Principia Biopharma Inc. |
| 18259762 | PYRIDINE-2-AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Non-Final OA | BEIJING SYNTHETIC VACCINE BIOSCIENCES CO., LTD |
| 18210766 | KINASE MODULATORS AND METHODS OF USE THEREOF | Non-Final OA | SUNDANCE BIOSCIENCES, INC. |
| 18031678 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | Non-Final OA | Ranok Therapeutics (Hangzhou) Co. Ltd. |
| 17906617 | AMIDE DERIVATIVES | Final Rejection | RYVU THERAPEUTICS S.A. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy